Related Experiment Video

Updated: Feb 10, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

[Selection of direct-acting antiviral agents for chronic hepatitis C infection]

Y J He1, Z H Liu, J L Hou

  • 1Institute of Hepatology, Southern Medical University, Guangzhou 510515, China.

Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology
|May 28, 2018
PubMed

Insights

Direct-acting antiviral agents (DAAs) offer a cure for hepatitis C virus (HCV) infection by targeting its life cycle. Careful consideration of factors influencing efficacy and safety is crucial when selecting DAA regimens.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) infection remains a significant global health challenge.
  • Direct-acting antiviral agents (DAAs) represent a breakthrough in HCV treatment, offering high cure rates.
  • Standardization and simplification of treatment regimens are ongoing goals in HCV management.

Purpose of the Study:

  • To review the development history of direct-acting antiviral agents (DAAs) for HCV.
  • To analyze factors influencing the efficacy and safety of DAAs.
  • To provide an overview of currently available and approved DAA therapeutic regimens.

Main Methods:

  • Literature review of scientific publications and clinical trial data on DAAs.
  • Analysis of factors affecting DAA treatment outcomes, including patient characteristics and viral genetics.
  • Compilation of information on approved DAA regimens in the domestic market.

Main Results:

  • DAAs target specific stages of the HCV replication cycle, leading to viral elimination.
  • Efficacy and safety of DAAs can be influenced by various patient-related and virus-related factors.
  • A range of DAA regimens are available, varying in composition and application.

Conclusions:

  • DAAs have revolutionized HCV treatment, offering a curative option.
  • Personalized selection of DAA regimens based on individual patient factors is essential for optimal outcomes.
  • Continued research and development are vital for further improving HCV elimination strategies.

Keywords:
Antiviral therapyClinical trialDirect-acting antiviral agentsHepatitis C, chronicTherapy

More Related Videos

Assays for the Identification of Novel Antivirals against Bluetongue Virus12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

14.6K
Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

14.5K

Related Concept Videos

Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
2.9K
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.9K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.8K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.4K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
2.2K